Related Experiment Video
Updated: Aug 10, 2026
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
Anthracycline-induced cardiac injury using a cardiac cell line: potential for gene therapy studies
T L'Ecuyer1, M S Horenstein, R Thomas
1Department of Pediatrics, Wayne State University College of Medicine, Detroit, MI, USA. thlecuye@med.wayne.edu
Abstract:
Anthracyclines are effective antitumor agents whose chief limitation has been cardiotoxicity directly related to free radical production. Therefore, strategies designed to selectively overexpress antioxidant proteins in the heart could protect against drug-induced toxicity and allow higher doses of chemotherapy. However, to date an adequate cardiac model system that is susceptible to anthracycline injury and can express foreign genes in a controlled fashion has been lacking. Developing a cardiac model system would permit examination of the relationship between the expression level of a potentially protective foreign gene and the degree of protection from injury. In this study we have examined the potential of the H9C2 rat cardiac myocyte cell line in this regard. H9C2 cells differentiate in a reproducible fashion, as shown by progressive increases in muscle tropomyosin-expressing cells, the organization of this thin filament protein, and the percentage of muscle cells contained within myotubes. Exposure of this cell line to the anthracycline doxorubicin produces cell injury as indicated by release of the intracellular enzyme lactate dehydrogenase into the culture medium. This injury is preceded by generation of reactive oxygen species, indicated by fluorescence after loading with carboxy-dichlorodihydrofluorescein diacetate. Stable transfection of H9C2 cells with a plasmid producing a tetracycline transactivator protein allows foreign genes to be expressed at a level tightly controlled by the concentration of tetracycline in the culture medium. Since H9C2 cells differentiate, can be injured by anthracycline exposure, and can express foreign genes at controllable levels, this is a suitable system in which to design genetic approaches to prevent this important clinical problem.
Insights
This study introduces H9C2 rat cardiac myocyte cells as a model to combat anthracycline cardiotoxicity. These cells can be genetically modified to test antioxidant therapies, potentially protecting the heart during chemotherapy.
Area of Science:
- Cardiology
- Pharmacology
- Molecular Biology
Background:
- Anthracyclines are vital chemotherapy drugs but cause dose-limiting cardiotoxicity due to free radical production.
- Strategies to enhance cardiac antioxidant defenses could mitigate this toxicity, allowing for higher chemotherapy doses.
- A suitable cardiac cell model is needed to study gene-drug interactions and develop protective therapies.
Purpose of the Study:
- To evaluate the H9C2 rat cardiac myocyte cell line as a model for studying anthracycline-induced cardiotoxicity.
- To determine if H9C2 cells can be genetically engineered to express foreign genes in a controlled manner for protective strategies.
- To establish a system for investigating the relationship between antioxidant gene expression and protection against doxorubicin injury.
Main Methods:
- H9C2 cells were assessed for differentiation markers like muscle tropomyosin and myotube formation.
- Doxorubicin exposure was used to induce cell injury, measured by lactate dehydrogenase release.
- Reactive oxygen species generation was detected using carboxy-dichlorodihydrofluorescein diacetate.
- Stable transfection with a tetracycline-inducible transactivator allowed controlled foreign gene expression.
Main Results:
- H9C2 cells demonstrated reproducible differentiation into myotubes.
- Doxorubicin treatment caused significant cell injury, preceded by increased reactive oxygen species.
- Stable H9C2 transfectants exhibited tetracycline-regulatable foreign gene expression.
- The H9C2 cell line proved susceptible to anthracycline injury and capable of controlled gene expression.
Conclusions:
- The H9C2 rat cardiac myocyte cell line is a suitable model for investigating anthracycline cardiotoxicity.
- This system allows for the controlled expression of genes aimed at preventing drug-induced cardiac damage.
- The H9C2 model provides a platform for developing genetic strategies to overcome chemotherapy-related heart problems.
